Regenxbio's Duchenne Gene Therapy Shows Improved Muscle Function, Clean Safety in Trial
RGNX sits 83% above its 52-week low of $5.035 on light trading volume (0.3× avg).
Summary
REGENXBIO announced positive interim data from an early-to-mid stage study of its experimental gene therapy for Duchenne muscular dystrophy, showing continued improvement in muscle function and a clean safety profile. This positive development is highly significant, as it follows the company's recent disclosure of "substantial doubt about its ability to continue as a going concern" and "critical FDA setbacks for other gene therapies" in its March 5th 10-K filing. The favorable trial results provide a much-needed positive catalyst, potentially improving investor sentiment and offering a lifeline amidst recent financial and regulatory challenges. Traders will be watching for further details on this program's progression and its impact on the company's long-term viability.
At the time of this announcement, RGNX was trading at $9.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $475.4M. The 52-week trading range was $5.04 to $16.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.